vs
杜比实验室（DLB）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
杜比实验室的季度营收约是REPLIGEN CORP的2.0倍（$395.6M vs $197.9M），杜比实验室净利率更高（24.0% vs 6.7%，领先17.3%），REPLIGEN CORP同比增速更快（13.6% vs 7.1%），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 13.9%）
杜比实验室是一家美国科技企业，专注于音频降噪、音频编码压缩、空间音频及高动态范围（HDR）影像等技术的研发，旗下技术广泛授权给全球各地的消费电子制造商使用，助力终端产品为用户带来更出色的视听体验。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
DLB vs RGEN — 直观对比
营收规模更大
DLB
是对方的2.0倍
$197.9M
营收增速更快
RGEN
高出6.6%
7.1%
净利率更高
DLB
高出17.3%
6.7%
两年增速更快
RGEN
近两年复合增速
13.9%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $395.6M | $197.9M |
| 净利润 | $94.9M | $13.3M |
| 毛利率 | 88.7% | 52.5% |
| 营业利润率 | 28.5% | 9.0% |
| 净利率 | 24.0% | 6.7% |
| 营收同比 | 7.1% | 13.6% |
| 净利润同比 | 3.4% | 143.9% |
| 每股收益（稀释后） | $0.99 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DLBRGEN
| Q2 26 | $395.6M | — | ||
| Q1 26 | $346.7M | — | ||
| Q4 25 | $346.7M | $197.9M | ||
| Q3 25 | $307.0M | $188.8M | ||
| Q2 25 | $315.5M | $182.4M | ||
| Q1 25 | $369.6M | $169.2M | ||
| Q4 24 | $357.0M | $174.1M | ||
| Q3 24 | $304.8M | $154.9M |
净利润DLBRGEN
| Q2 26 | $94.9M | — | ||
| Q1 26 | $53.3M | — | ||
| Q4 25 | $53.3M | $13.3M | ||
| Q3 25 | $49.3M | $14.9M | ||
| Q2 25 | $46.1M | $14.9M | ||
| Q1 25 | $91.8M | $5.8M | ||
| Q4 24 | $67.8M | $-30.3M | ||
| Q3 24 | $58.6M | $-654.0K |
毛利率DLBRGEN
| Q2 26 | 88.7% | — | ||
| Q1 26 | 87.5% | — | ||
| Q4 25 | 87.5% | 52.5% | ||
| Q3 25 | 87.1% | 53.2% | ||
| Q2 25 | 86.1% | 50.0% | ||
| Q1 25 | 90.3% | 53.6% | ||
| Q4 24 | 88.6% | 26.1% | ||
| Q3 24 | 88.8% | 50.0% |
营业利润率DLBRGEN
| Q2 26 | 28.5% | — | ||
| Q1 26 | 17.9% | — | ||
| Q4 25 | 17.9% | 9.0% | ||
| Q3 25 | 9.7% | 8.9% | ||
| Q2 25 | 15.1% | 7.6% | ||
| Q1 25 | 29.2% | 3.9% | ||
| Q4 24 | 22.4% | -17.7% | ||
| Q3 24 | 15.2% | -5.1% |
净利率DLBRGEN
| Q2 26 | 24.0% | — | ||
| Q1 26 | 15.4% | — | ||
| Q4 25 | 15.4% | 6.7% | ||
| Q3 25 | 16.1% | 7.9% | ||
| Q2 25 | 14.6% | 8.2% | ||
| Q1 25 | 24.8% | 3.4% | ||
| Q4 24 | 19.0% | -17.4% | ||
| Q3 24 | 19.2% | -0.4% |
每股收益（稀释后）DLBRGEN
| Q2 26 | $0.99 | — | ||
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.55 | $0.24 | ||
| Q3 25 | $0.50 | $0.26 | ||
| Q2 25 | $0.48 | $0.26 | ||
| Q1 25 | $0.94 | $0.10 | ||
| Q4 24 | $0.70 | $-0.55 | ||
| Q3 24 | $0.59 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $594.7M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $2.6B | $2.1B |
| 总资产 | $3.2B | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资DLBRGEN
| Q2 26 | $594.7M | — | ||
| Q1 26 | $644.6M | — | ||
| Q4 25 | $644.6M | $767.6M | ||
| Q3 25 | $702.6M | $748.7M | ||
| Q2 25 | $699.3M | $708.9M | ||
| Q1 25 | $626.6M | $697.2M | ||
| Q4 24 | $520.8M | $757.4M | ||
| Q3 24 | $482.0M | $784.0M |
总债务DLBRGEN
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — |
股东权益DLBRGEN
| Q2 26 | $2.6B | — | ||
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.6B | $2.1B | ||
| Q3 25 | $2.6B | $2.1B | ||
| Q2 25 | $2.6B | $2.1B | ||
| Q1 25 | $2.6B | $2.0B | ||
| Q4 24 | $2.5B | $2.0B | ||
| Q3 24 | $2.5B | $2.0B |
总资产DLBRGEN
| Q2 26 | $3.2B | — | ||
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $2.9B | ||
| Q3 25 | $3.2B | $2.9B | ||
| Q2 25 | $3.2B | $2.9B | ||
| Q1 25 | $3.2B | $2.9B | ||
| Q4 24 | $3.2B | $2.8B | ||
| Q3 24 | $3.1B | $2.8B |
负债/权益比DLBRGEN
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $147.3M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | — | $17.6M |
| 自由现金流率自由现金流/营收 | — | 8.9% |
| 资本支出强度资本支出/营收 | — | 4.1% |
| 现金转化率经营现金流/净利润 | 1.55× | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流DLBRGEN
| Q2 26 | $147.3M | — | ||
| Q1 26 | $54.8M | — | ||
| Q4 25 | $54.8M | $25.7M | ||
| Q3 25 | $472.2M | $48.1M | ||
| Q2 25 | $67.7M | $28.6M | ||
| Q1 25 | $174.9M | $15.0M | ||
| Q4 24 | $106.8M | $39.2M | ||
| Q3 24 | $327.3M | $49.3M |
自由现金流DLBRGEN
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | $17.6M | ||
| Q3 25 | $435.9M | $43.4M | ||
| Q2 25 | $61.3M | $21.5M | ||
| Q1 25 | $168.0M | $11.4M | ||
| Q4 24 | $100.0M | $33.6M | ||
| Q3 24 | $297.2M | $42.3M |
自由现金流率DLBRGEN
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 14.5% | 8.9% | ||
| Q3 25 | 142.0% | 23.0% | ||
| Q2 25 | 19.4% | 11.8% | ||
| Q1 25 | 45.5% | 6.8% | ||
| Q4 24 | 28.0% | 19.3% | ||
| Q3 24 | 97.5% | 27.3% |
资本支出强度DLBRGEN
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.3% | 4.1% | ||
| Q3 25 | 11.8% | 2.5% | ||
| Q2 25 | 2.0% | 3.9% | ||
| Q1 25 | 1.9% | 2.1% | ||
| Q4 24 | 1.9% | 3.2% | ||
| Q3 24 | 9.8% | 4.5% |
现金转化率DLBRGEN
| Q2 26 | 1.55× | — | ||
| Q1 26 | 1.03× | — | ||
| Q4 25 | 1.03× | 1.93× | ||
| Q3 25 | 9.57× | 3.23× | ||
| Q2 25 | 1.47× | 1.92× | ||
| Q1 25 | 1.91× | 2.57× | ||
| Q4 24 | 1.57× | — | ||
| Q3 24 | 5.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DLB
| Licensing | $372.2M | 94% |
| Products and services | $23.4M | 6% |
RGEN
暂无分部数据
